The nasolacrimal duct is a passage from the eye to the nose. Epiphora is a disease in which the nasolacrimal duct has become narrow or obstructed, decreasing its tear discharge function such that tears cannot be discharged through the nose but overflow externally. Most cases of epiphora are caused by nasolacrimal duct obstruction that does not accompany any anatomical abnormality, and as such, treatment usually involves non-surgical treatment with drugs or guiders (tubes) that are inserted to open the nasolacrimal duct. Various drugs and guiders are being developed to open the nasolacrimal duct, but there has yet to be an animal model for accurately evaluating their effects, which limits preclinical study. The existing dacryocystorhinostenosis animal model does not stably maintain the nasolacrimal duct obstruction, and the dacryocystorhinostenosis effect declines before accurately measuring the treatment effects of drugs and guiders. Accordingly, the present invention is an dacryocystorhinostenosis animal model that stably maintains the nasolacrimal duct obstruction and its production method.
The present invention is a dacryocystorhinostenosis animal model that stably maintains the nasolacrimal duct obstruction and its production method, and the invention’s animal model uses a hydrogel that contains an adhesion-inducing substance to provide an animal model in which the dacryocystorhinostenosis effect is long-lasting. Consequently, this invention can accurately evaluate the effects of drugs and guiders used for the treatment of nasolacrimal duct obstruction, and it is expected that it will be used widely in the field of medical treatment development.